Literature DB >> 7683661

Mapping of neutralizing epitopes and the receptor binding site of human interleukin 1 beta.

P L Simon1, V Kumar, J S Lillquist, P Bhatnagar, R Einstein, J Lee, T Porter, D Green, G Sathe, P R Young.   

Abstract

Antibodies to synthetic peptides of human interleukin 1 beta (IL-1 beta) and to recombinant human IL-1 beta were used to identify epitopes of IL-1 beta associated with the neutralization of its biological activity. Analysis of antisera raised to 17 synthetic peptides derived from the mature IL-1 beta sequence showed that five regions (residues 6-15, 49-80, 58-80, 92-101, and 120-133) were both immunoprecipitating and neutralizing. Using a hexamer epitope mapping method, comparison of the regions recognized by four neutralizing rabbit antisera with those recognized by a rabbit antiserum raised to denatured IL-1 beta suggested two further neutralizing epitopes, residues 39-48 and 83-95. Finally, a neutralizing monoclonal antibody was shown to bind to the peptides 6-11 and 87-95 by peptide binding and mutagenesis. All of these regions appear predominantly on one face of IL-1 beta. The effect of mutations in residues 4-11 and 88-97, which lie within this face, on receptor binding and biological activity was determined. Most of the mutations tested affected both receptor binding and activity, whereas mutations in another face of IL-1 beta (residues 74-80) had no effect. Purification of two of the mutants with reduced bioactivity and receptor binding and analysis by two-dimensional NMR indicated no gross changes in tertiary structure. A third mutant had reduced bioactivity in two different bioassays but no change in receptor binding. Although two-dimensional NMR revealed no gross changes in conformation, small changes did occur at a site distal from that mutated. The data are consistent with other epitope mapping and receptor binding mutagenesis data and suggest that the neutralizing antibodies and receptor recognize different but overlapping regions of IL-1 beta.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683661

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.

Authors:  J A Symons; P R Young; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

2.  Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes.

Authors:  Andreas Lingel; Thomas M Weiss; Marc Niebuhr; Borlan Pan; Brent A Appleton; Christian Wiesmann; J Fernando Bazan; Wayne J Fairbrother
Journal:  Structure       Date:  2009-10-14       Impact factor: 5.006

Review 3.  Benchmarking B-cell epitope prediction for the design of peptide-based vaccines: problems and prospects.

Authors:  Salvador Eugenio C Caoili
Journal:  J Biomed Biotechnol       Date:  2010-03-30

4.  Neuraminidase-1, a subunit of the cell surface elastin receptor, desialylates and functionally inactivates adjacent receptors interacting with the mitogenic growth factors PDGF-BB and IGF-2.

Authors:  Aleksander Hinek; Tetyana D Bodnaruk; Severa Bunda; Yanting Wang; Kela Liu
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

5.  Conservation and evolution of cis-regulatory systems in ascomycete fungi.

Authors:  Audrey P Gasch; Alan M Moses; Derek Y Chiang; Hunter B Fraser; Mark Berardini; Michael B Eisen
Journal:  PLoS Biol       Date:  2004-11-09       Impact factor: 8.029

6.  Structural differences between the putative carbohydrate-recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling.

Authors:  Gérard Vergoten; Jean-Pierre Zanetta
Journal:  Glycoconj J       Date:  2007-03-06       Impact factor: 3.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.